Nina Goodheart, vice president of renal denervation at Medtronic, said "signals" in the data suggest the treatment might benefit certain patients, depending on what drugs they were taking.
It is also possible that the procedure wasn't performed correctly or completely during the study, Ms. Goodheart
said, citing what she
said were small but encouraging pieces of data that weren't included in the New England Journal of Medicine manuscript
The company is in discussions with the FDA
about how to move forward with a new clinical trial, Ms. Goodheart
"We've seen enough positive clinical signals that this therapy warrants further investigation," she
said in interview.
"Are we willing to invest in another clinical trial?
tone contrasted starkly with that of Medtronic
executives in January, when the company first said the study had failed, and in February, when it wrote off $236 million related to its renal-denervation program--acquired through an $800 million acquisition in 2010.
has done significant data analysis in the months since, Ms. Goodheart
said, pointing out that there is a large unmet medical need, and market opportunity, to treat certain hypertensive patients.